National Institutes of Health: Adenocarcinoma, Mucinous trials

The registry lists 16 Adenocarcinoma, Mucinous studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 7Phase 2 5Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryCompletedNCT01802320Phase 2Results posted
• Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by SurgeryTerminatedNCT00835679Early Phase 1Results posted
• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT00565851Phase 3Results posted
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00262847Phase 3Results posted
• Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal CancerCompletedNCT00100841Phase 2Results posted
• Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal CancerCompletedNCT00068692Phase 3Results posted
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial CancerCompletedNCT01440998Phase 1
• Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal CancerTerminatedNCT01198535Phase 1
• Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01074411Phase 1
• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00989651Phase 1
• A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal CancerCompletedNCT00060411Phase 1
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal CancerTerminatedNCT00052585Phase 2
• Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal CancerCompletedNCT00005036Phase 3
• Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal CancerCompletedNCT00003799Phase 1
• Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal CancerTerminatedNCT00002796Phase 1/2